

## Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib

**Bin Zhao<sup>1</sup> and Hong Zhao<sup>1,2</sup>**

<sup>1</sup> Center for Scientific Research, The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325027, China

<sup>2</sup> Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150081, China

**Published:** January 04, 2019

**Copyright:** Zhao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct author affiliation information is given below:

**Hong Zhao<sup>1,2</sup>**

Original article: Oncotarget. 2017; 8:93813-93824. <https://doi.org/10.18632/oncotarget.21217>